VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema

Assistance Publique - Hôpitaux de Paris1 site in 1 country72 target enrollmentJanuary 2005

ConditionsDiabetic Macular Edema Diabetes

InterventionsVitrectomy Intravitreal triamcinolone injections Laser photocoagulation

DrugsIntravitreal triamcinolone injections

Overview

Phase: Phase 3
Intervention: Vitrectomy
Conditions: Diabetic Macular Edema
Sponsor: Assistance Publique - Hôpitaux de Paris
Enrollment: 72
Locations: 1
Primary Endpoint: Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Macular edema is the main cause of vision loss in diabetic patients. Its treatment is mainly based on laser photocoagulation, but has limited results. Alternative treatment are under investigation, such as vitrectomy and intravitreal injections of triamcinolone .The aim of VITRILASE is to compare the efficacy of these two treatments to laser photocoagulation for diabetic macular edema.

Detailed Description

It is a randomized study with three arms * vitrectomy * repeat intravitreal triamcinolone injections * laser photocoagulation

Registry

clinicaltrials.gov

Start Date

January 2005

End Date

December 2009

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Assistance Publique - Hôpitaux de Paris

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient with type 1 or type 2 diabetes
•Visual acuity (VA) : 0.1≤ VA \< 0.5 (35 ≤ ETDRS score \< 70)
•Patient with diffuse diabetic macular edema , as defined by :§ Retinal thickening involving the center of the macular on biomicroscopy§ AND diffuse leakage on fluorescein angiography .
•Macular thickness in the central area 1000 µm in diameter ³ 300 µm.
•Patient with :· Either diffuse diabetic macular edema · Or combined diffuse and focal diabetic macular edema with persistent diffuse macular edema 6 months after laser treatment of the focal edema .
•Systolic blood pressure ≤ 160 mmHg and diastolic blood pressure ≤ 90 mmHg.,
•HbA1c \< 10%.

Exclusion Criteria

•Patient with tractional diabetic macular edema, as defined by· A taut, thickened posterior hyaloid on biomicroscopy AND/OR· a thickened , highly reflective posterior hyaloid on OCT , partially detached from the posterior pole, and exerting a traction on the macula
•Active proliferative diabetic retinopathy (ETDRS stage 61 or more severe)
•Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), or organized central hard exudate plaque³ 1 disk area
•Hypertensive retinopathy
•Epiretinal membrane.
•Rubeosis irides .
•Patient requiring immediate panretinal photocoagulation or panretinal photocoagulation performed within the past 6 months .
•History of chronic glaucoma in the study eye
•History of elevated intraocular pressure ≥30 mm Hg and/or alteration of visual field
•Concomitant therapy with systemic or topical ocular corticosteroids within the last 15 days .

Arms & Interventions

1

Vitrectomy

Intervention: Vitrectomy

2

Intravitreal triamcinolone injections

Intervention: Intravitreal triamcinolone injections

3

Laser photocoagulation

Intervention: Laser photocoagulation

Outcomes

Primary Outcomes

Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years

Time Frame: at 2 years

Secondary Outcomes

Central macular thickness on Optical Coherence Tomography (OCT)(at 8, 12 and 24 months)
Percentage of patients with visual gain ≥ 3 ETDRS lines(8, 12 and 22 months)
Progression of lens opacities(During the all follow-up)
Frequency of complications(During the all follow-up)
Results analysis according to preoperative vitreous detachment, honeycomb macular edema on fluorescein angiography(at inclusion time)
Evolution of visual fiends and posterior vitreous detachment(At inclusion time and 2 years)
Percentage of patients presenting an increase of 2 line or more of best corrected visual acuity on ETDRS charts(after 1 year, 22 months and 24 months of follow-up)
Percentage of patients presenting an decrease of 2 line or more of best corrected visual acuity on ETDRS charts(after 1 year, 22 months and 24 months of follow-up)
Scores ETDRS(after 1 year, 22 months and 24 months of follow-up)
Mean best corrected visual acuity during follow-up period(during the all follow-up)
Progression of retinopathy diabetic in each group(during the all follow-up)
Outcome in respect to posterior vitreal detachment (PVD) stage(during the all follow-up)
PVD stage evolution during the follow-yp in laser and triamcinolone group(first and last exam)
Evolution of visual field in each group(inclusion and last visit)